Drug
Latrepirdine clinical trials
Also written Dimebon and PF-01913539.
- studies test it
- 27
- open now
- 0
- in phase 3
- 9
- first study started
- 2005
How studies write it
Studies that test it under each name
Studies by the year they started
27 studies that test it; most in 2009 (16)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 4 |
| 2009 | 16 |
| 2010 | 3 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 13
- Phase 2
- 6
- Phase 3
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 27 · Other 0
Pfizer (15) · Medivation, Inc. (11) · Bigespas LTD (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses latrepirdine is read from its arms, and is right about nine times in ten.
Testing it · 27
- DMB-I in the Treatment of Alzheimer Type DementiaCompletedPhase 2Bigespas LTDNCT06292351Written as DMB-I (Dimebon)
- A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's DiseaseCompletedPhase 3PfizerNCT00838110Written as Dimebon
- A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy SubjectsCompletedPhase 1PfizerNCT00827034Written as Dimebon
- A Safety and Efficacy Study of Dimebon in Patients With Huntington DiseaseCompletedPhase 3Medivation, Inc.NCT00920946Written as Dimebon
- An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington DiseaseTerminatedPhase 3Medivation, Inc.NCT01085266Written as Dimebon (latrepirdine)
- Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on DonepezilCompletedPhase 3Medivation, Inc.NCT00829374Written as Dimebon
- A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's DiseaseCompletedPhase 3Medivation, Inc.NCT00675623Written as Dimebon
- An Extension of the CONCERT Protocol (DIM18)TerminatedPhase 3Medivation, Inc.NCT01152216Written as Dimebon
- A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's DiseaseTerminatedPhase 3Medivation, Inc.NCT00954590Written as Dimebon (latrepirdine)
- Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's DiseaseTerminatedPhase 2Medivation, Inc.NCT00704782Written as dimebon
- Double-blind, Placebo-controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's DiseaseCompletedPhase 2Medivation, Inc.NCT00377715Written as Dimebon
- Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus DonepezilCompletedPhase 1Medivation, Inc.NCT00829816Written as Dimebon
- A Study of the Novel Drug Dimebon in Patients With Huntington's DiseaseCompletedPhase 2Medivation, Inc.NCT00497159Written as Dimebon
- A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug UsersCompletedPhase 1PfizerNCT00975481Written as dimebon
- An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's DiseaseTerminatedPhase 3PfizerNCT00939783Written as Dimebon
- A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's DiseaseTerminatedPhase 3PfizerNCT00912288Written as Dimebon 20 mg po TID
- A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy SubjectsCompletedPhase 1PfizerNCT00825084Written as Dimebon
- A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's DiseaseWithdrawnPhase 2PfizerNCT01066481Written as PF-01913539 5 mg
- A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The SkinCompletedPhase 1PfizerNCT00990613Written as Dimebon IR
- A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)CompletedPhase 1PfizerNCT00988624Written as Dimebon IR Tablet
Codes
What other systems call latrepirdine · ClinicalTrials.gg INT002480
- MeSH (NLM) C010119latrepirdineOne source NLM
- UNII (FDA) OD9237K1Z6LATREPIRDINEConfirmed FDA, NLM, Wikidata
- Wikidata Q408580latrepirdineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C78757LatrepirdineOne source FDA
- DrugBank DB11725One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C010119 | latrepirdine | One source NLM |
| UNII (FDA) | OD9237K1Z6 | LATREPIRDINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q408580 | latrepirdine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C78757 | Latrepirdine | One source FDA |
| DrugBank | DB11725 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.